Phase 3 ECHO Trial: Study Design and Efficacy Data

This case report explores the diagnosis and treatment of extranodal NK/T-cell lymphoma, highlighting clinical challenges and advancements in pathology and therapy.

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

LYL314 elicited a complete response rate of 72%, with 71% of responses lasting for 6 or more months in patients with large B-cell lymphoma in the third or later lines of therapy.

Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.

No new safety signals were observed with liso-cel, with the therapy showing low rates of severe cytokine release syndrome and neurologic events.

JNJ’4496 at 75 M CAR T cells elicited an ORR of 100% in patients with relapsed or refractory large B-cell lymphoma who received 1 prior line of treatment.